{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:11:05Z","timestamp":1777284665855,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1124\/dmd.118.086090","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T20:14:18Z","timestamp":1554754458000},"page":"657-664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mechanism of Reductive Metabolism and Chiral Inversion of Proton Pump Inhibitors"],"prefix":"10.1016","volume":"47","author":[{"given":"Chongzhuang","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojian","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.118.086090_bib1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nrd915","article-title":"Putting chirality to work: the strategy of chiral switches","volume":"1","author":"Agranat","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.118.086090_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2165\/00003088-200140060-00003","article-title":"Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole","volume":"40","author":"Andersson","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.118.086090_bib3","first-page":"203","article-title":"In vitro transesterification of cocaethylene (ethylcocaine) in the presence of ethanol. esterase-mediated ethyl ester exchange esterase-mediated ethyl ester exchange","volume":"26","author":"Bourland","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.086090_bib4","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/00268970902799890","article-title":"Reactivity of acetanilides in the alkaline hydrolysis reaction: theory vs. experiment","volume":"107","author":"Cheshmedzhieva","year":"2009","journal-title":"Mol Phys"},{"key":"10.1124\/dmd.118.086090_bib5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/00498254.2017.1307470","article-title":"Stereoselective and nonstereoselective pharmacokinetics of rabeprazole\u2014an overview","volume":"48","author":"Dash","year":"2018","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.118.086090_bib6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1042\/bj2280363","article-title":"Metabolism of the lipid peroxidation product 4-hydroxynonenal by isolated hepatocytes and by liver cytosolic fractions","volume":"228","author":"Esterbauer","year":"1985","journal-title":"Biochem J"},{"key":"10.1124\/dmd.118.086090_bib7","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.118.086090_bib8","first-page":"595","article-title":"Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions","volume":"57","author":"Fuhr","year":"2002","journal-title":"Pharmazie"},{"key":"10.1124\/dmd.118.086090_bib9","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/bmc.2932","article-title":"The chiral bioconversion and preclinical pharmacokinetic analysis of (R)-(+)-rabeprazole in beagle dogs by HPLC and HPLC-MS\/MS","volume":"27","author":"Gao","year":"2013","journal-title":"Biomed Chromatogr"},{"key":"10.1124\/dmd.118.086090_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0006-2952(00)00301-4","article-title":"Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes","volume":"60","author":"Hamman","year":"2000","journal-title":"Biochem Pharmacol"},{"issue":"Suppl 6","key":"10.1124\/dmd.118.086090_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2036.2004.02161.x","article-title":"Review article: relationship between the metabolism and efficacy of proton pump inhibitors\u2014focus on rabeprazole","volume":"20","author":"Horn","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/dmd.118.086090_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2036.1995.tb00394.x","article-title":"Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole","volume":"9","author":"Huber","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/dmd.118.086090_bib13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/dmd.116.073239","article-title":"Stereoselective pharmacokinetics and chiral inversion of ibuprofen in adjuvant-induced arthritic rats","volume":"45","author":"Ikuta","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 3","key":"10.1124\/dmd.118.086090_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2036.1999.00022.x","article-title":"Review article: cytochrome P450 and the metabolism of proton pump inhibitors\u2014emphasis on rabeprazole","volume":"13","author":"Ishizaki","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/dmd.118.086090_bib15","first-page":"716","article-title":"Cytochrome P450 responsible for the stereoselective S-oxidation of flosequinan in hepatic microsomes from rats and humans","volume":"25","author":"Kashiyama","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.086090_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0006-2952(94)90093-0","article-title":"Chiral inversion of drug: role of intestinal bacteria in the stereoselective sulphoxide reduction of flosequinan","volume":"48","author":"Kashiyama","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.118.086090_bib17","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1124\/dmd.104.000752","article-title":"Differentiation of gut and hepatic first-pass loss of verapamil in intestinal and vascular access-ported (IVAP) rabbits","volume":"32","author":"Kunta","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.086090_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0378-4347(92)80605-P","article-title":"Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column","volume":"577","author":"Landes","year":"1992","journal-title":"J Chromatogr A"},{"key":"10.1124\/dmd.118.086090_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.vascn.2017.05.004","article-title":"The determination of hepatic glutathione at tissue and subcellular level","volume":"88","author":"L\u0151rincz","year":"2017","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/dmd.118.086090_bib21","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/chir.20417","article-title":"Pyramidal inversion mechanism of simple chiral and achiral sulfoxides: a theoretical study","volume":"19","author":"Marom","year":"2007","journal-title":"Chirality"},{"key":"10.1124\/dmd.118.086090_bib22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/00498258209052468","article-title":"The metabolism of [14C]cimetidine in man","volume":"12","author":"Mitchell","year":"1982","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.118.086090_bib23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jpba.2005.12.016","article-title":"Determination of rabeprazole enantiomers and their metabolites by high-performance liquid chromatography with solid-phase extraction","volume":"41","author":"Miura","year":"2006","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/dmd.118.086090_bib24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.2005.02381.x","article-title":"Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine","volume":"60","author":"Miura","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.086090_bib25","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1124\/dmd.118.081570","article-title":"Biotransformation of ilaprazole in human liver microsomes and human: role of CYP3A4 in ilaprazole clearance and drug-drug interaction","volume":"46","author":"Pu","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.086090_bib26","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1021\/ja01020a019","article-title":"Thermal racemization of diaryl alkyl aryl and dialkyl sulfoxides by pyramidal inversion","volume":"90","author":"Rayner","year":"1968","journal-title":"J Am Chem Soc"},{"key":"10.1124\/dmd.118.086090_bib27","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1021\/cr00088a005","article-title":"Intermolecular interactions from a natural bond orbital, donor-acceptor viewpoint","volume":"88","author":"Reed","year":"1988","journal-title":"Chem Rev"},{"key":"10.1124\/dmd.118.086090_bib28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1063\/1.449486","article-title":"Natural-population analysis","volume":"83","author":"Reed","year":"1985","journal-title":"J Chem Phys"},{"key":"10.1124\/dmd.118.086090_bib29","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1021\/tx9801817","article-title":"Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites","volume":"11","author":"Reist","year":"1998","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.118.086090_bib30","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jchromb.2006.07.047","article-title":"A simple and sensitive bioanalytical assay for simultaneous determination of omeprazole and its three major metabolites in human blood plasma using RP-HPLC after a simple liquid-liquid extraction procedure","volume":"844","author":"Rezk","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/dmd.118.086090_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.5414\/CPP44557","article-title":"Mass balance study of [14C] rabeprazole following oral administration in healthy subjects","volume":"44","author":"Setoyama","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.086090_bib32","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1124\/dmd.113.056713","article-title":"Quantitative determination of absorption and first-pass metabolism of apicidin, a potent histone deacetylase inhibitor","volume":"42","author":"Shin","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.086090_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","article-title":"Pharmacokinetics and pharmacodynamics of the proton pump inhibitors","volume":"19","author":"Shin","year":"2013","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1124\/dmd.118.086090_bib34","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1046\/j.1365-2036.2001.01108.x","article-title":"Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH","volume":"15","author":"Shirai","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/dmd.118.086090_bib35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-1-4939-7258-6_20","article-title":"Monitoring of methionine sulfoxide content and methionine sulfoxide reductase activity","volume":"1661","author":"Tarrago","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1124\/dmd.118.086090_bib36","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1248\/cpb.30.4585","article-title":"Involvement of liver aldehyde oxidase in sulfoxide reduction","volume":"30","author":"Tatsumi","year":"1982","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1124\/dmd.118.086090_bib37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/03639049409039080","article-title":"Stereoisomeric drugs: FDA\u2019s policy statement and the impact on drug development","volume":"20","author":"Tomaszewski","year":"1994","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1124\/dmd.118.086090_bib38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2125.2005.02556.x","article-title":"Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status","volume":"61","author":"Uno","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.086090_bib39","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jchromb.2005.07.027","article-title":"Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study","volume":"824","author":"Uno","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/dmd.118.086090_bib40","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0731-7085(98)00059-4","article-title":"Pharmaceutical development and specification of stereoisomers","volume":"17","author":"Williams","year":"1998","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/dmd.118.086090_bib41","first-page":"370","article-title":"Studies on chiral inversion of dextropantoprazole in human","volume":"39","author":"Xie","year":"2004","journal-title":"Yao Xue Xue Bao"},{"key":"10.1124\/dmd.118.086090_bib42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.redox.2017.01.014","article-title":"Oral administration of \u03b3-glutamylcysteine increases intracellular glutathione levels above homeostasis in a randomised human trial pilot study","volume":"11","author":"Zarka","year":"2017","journal-title":"Redox Biol"},{"key":"10.1124\/dmd.118.086090_bib43","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.3748\/wjg.14.2617","article-title":"Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors?","volume":"14","author":"Zhou","year":"2008","journal-title":"World J Gastroenterol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.118.086090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:50:15Z","timestamp":1740055815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624079649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0090955624079649"],"URL":"https:\/\/doi.org\/10.1124\/dmd.118.086090","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism of Reductive Metabolism and Chiral Inversion of Proton Pump Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.118.086090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}